Navigating the complex landscape of crawling-type gastric adenocarcinomas:Insights and implications for clinical practice

作     者：Hai-Bo Yu Ke-Feng Jia Xing-Fen Wang Bao-Yu Li Qi Xin 

作者机构：LaboratoryThe Second Hospital of Tianjin Medical UniversityTianjin 300211China Department of RadiologyTianjin Third Central HospitalTianjin 300170China Department of PathologyThe Second Hospital of Tianjin Medical UniversityTianjin 300211China Department of Gastrointestinal SurgeryThe Second Hospital of Tianjin Medical UniversityTianjin 300211China Department of PathologyThe Third Central Hospital of TianjinTianjin 300170China 

出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文）)

年 卷 期：2024年第16卷第11期

页      面：4309-4314页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：The Third Central Hospital of Tianjin No.2019YNR3 

主　　题：Crawling-type gastric adenocarcinoma Diagnosis Pathology Endoscopy Treatment 

摘      要：In this editorial,we comment on an article by Xu et *** article describes a case of crawling-type gastric adenocarcinoma(CRA)distinguished by its rare occurrence and diagnostic *** reviewed the detailed case-report findings showcasing clinical,pathological,and molecular characteristics of CRA that shed light on its elusive nature and challenges for early detection and *** case underscored the significance of advanced diagnostic tools such as endoscopic submucosal *** was placed on the molecular peculiarities of CRA,including the higher mutation rates of genes such as TP53 and RHOA and the notable absence of HER2 amplification,differentiating it from more conventional forms of gastric *** this editorial,we advocate for a multidisciplinary approach to effectively manage this rare subtype and highlight the necessity for precision in both diagnostic and therapeutic ***,a heightened awareness urging the adoption of advanced diagnostic techniques and collaborative approaches is necessary among clinicians and *** aim to contribute to the ongoing discourse in gastrointestinal oncology,emphasizing the importance of recognizing and addressing the complexities associated with rare cancer subtypes such as CRA.